keyword
MENU ▼
Read by QxMD icon Read
search

HCV guidelines

keyword
https://www.readbyqxmd.com/read/28109264/health-related-quality-of-life-in-patients-with-chronic-hepatitis-c-receiving-sofosbuvir-based-treatment-with-and-without-interferon-a-prospective-observational-study-in-egypt
#1
Naglaa F A Youssef, Mohamed El Kassas, Amany Farag, Ashley Shepherd
BACKGROUND: The Egyptian government introduced the first directly acting antivirals (DAAs) into Egypt through the government funded National Treatment Program. As yet, there has been no investigation into the effects of these new DAAs therapies on patient reported outcomes (PROs). This study aimed to (1) assess the PROs (health-related quality of life (HRQoL), mental health and perceived social support) of HCV patients receiving DAAs therapy prior, during and at the end of therapy; (2) evaluate PROs of Interferon-free (dual) users versus Interferon-containing (triple) users cross the three different time periods; and (3) identify the predictors of HRQoL of DAAs therapy users cross the three different time periods...
January 21, 2017: BMC Gastroenterology
https://www.readbyqxmd.com/read/28098111/incidence-of-hepatitis-c-virus-seroconversion-among-hemodialysis-patients-in-the-nile-delta-of-egypt-a-single-center-study
#2
Amany Talaat Kamal, Mohamed Nazmy Farres, Abeer Mohamed Eissa, Naglaa Ahmed Arafa, Raafat Saad Abdel-Reheem
Egypt has the highest worldwide prevalence of hepatitis C virus (HCV) infection, caused in part by nosocomial transmission. Patients on hemodialysis (HD) are at especially high risk of infection. We aimed to estimate the incidence of seroconversion among HCV-negative patients undergoing regular HD at a unit in a large public hospital in the Nile Delta of Egypt, which implements the Egyptian Ministry of Health guidelines for infection control, and an isolation policy for hepatitis-positive patients. We also assessed the adherence to infection control practices and evaluated nurses and physicians' knowledge and attitude toward infection control procedures...
January 2017: Saudi Journal of Kidney Diseases and Transplantation
https://www.readbyqxmd.com/read/28097100/hepatitis-c-virus-a-review-of-treatment-guidelines-cost-effectiveness-and-access-to-therapy
#3
REVIEW
Shaina M Lynch, George Y Wu
Hepatitis C virus (HCV) infection remains a significant medical concern in the United States and around the world. It is still one of the leading causes of chronic liver disease, and, for more than 20 years, there has been little progress in the treatment of HCV infection. The advent of direct-acting antivirals (DAAs) initiated the era of high efficacy and well-tolerated medications with high cure rates. The efficacy of these medications has prompted many professional societies around the world to update their treatment guidelines to include DAAs as first-line treatment...
December 28, 2016: Journal of Clinical and Translational Hepatology
https://www.readbyqxmd.com/read/28087291/primary-care-perspectives-on-hepatitis-c-virus-screening-diagnosis-and-linking-patients-to-appropriate-care
#4
Edward Lebovics, Richard Torres, Lucinda K Porter
Enormous progress has been made in recent years toward effectively treating and curing patients with chronic hepatitis C (CHC). However, at least half of the possible 7 million individuals infected with hepatitis C virus (HCV) in the US remain undiagnosed. The formidable task of increasing the number of patients diagnosed, and subsequently linked to appropriate care has fallen to primary care clinicians, who are mandated by some US States to offer screening to individuals born between 1945 and 1965 (the Baby Boomer Generation)...
January 10, 2017: American Journal of Medicine
https://www.readbyqxmd.com/read/28046099/cost-effectiveness-of-treating-hepatitis-c-with-sofosbuvir-ledipasvir-in-germany
#5
Jona T Stahmeyer, Siegbert Rossol, Sebastian Liersch, Ines Guerra, Christian Krauth
BACKGROUND: Infections with the hepatitis C virus (HCV) are a global public health problem. Long-term consequences are the development of liver cirrhosis and hepatocellular carcinoma. Newly introduced direct acting antivirals, especially interferon-free regimens, have improved rates of sustained viral response above 90% in most patient groups and allow treating patients who were ineligible for treatment in the past. These new regimens have replaced former treatment and are recommended by current guidelines...
2017: PloS One
https://www.readbyqxmd.com/read/28042136/epidemiology-and-treatment-of-hepatocellular-carcinoma-in-thailand
#6
REVIEW
Soonthorn Chonprasertsuk, Ratha-Korn Vilaichone
Hepatocellular carcinoma (HCC) is the most frequent type of malignant liver tumor in Thailand. The high incidence rate of HCC reflects from chronic HBV infection in this endemic area. Some patients are asymptomatic at presentation whereas many of them presented at advanced stage of HCC with limited treatment options and grave outcome. The Barcelona Clinic Liver Cancer (BCLC) staging system and management allocation for HCC is widely accepted and used in many international guidelines including Thailand. Curative treatment is expected in early stage of HCC while palliative treatment, combination treatment and best supportive care are offered to advanced stage of HCC...
January 1, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28024124/developing-therapies-to-treat-hepatitis-c-infection-in-post-liver-transplant-recipients
#7
Thomas R McCarty, Joseph K Lim
Currently, hepatitis C virus (HCV) infection remains the most common indication for liver transplant in the United States (US) with almost universal HCV recurrence in the post-liver transplant setting. Previous interferon (IFN)-related efficacy and tolerability concerns about worsening liver function have limited treatment options for many patients with HCV-associated decompensated liver disease and post-liver transplant recipients. However, the last decade has seen a seen a radical shift in the management of HCV with multiple direct-acting antiviral (DAA) treatments that provide more effective, all-oral, IFN-free alternatives...
December 26, 2016: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28008868/effect-of-minor-populations-of-ns5a-and-ns5b-resistance-associated-variants-on-hcv-genotype-3-response-to-daclatasvir-plus-sofosbuvir-with-or-without-ribavirin
#8
Fiona McPhee, Dennis Hernandez, Nannan Zhou
BACKGROUND: Treatment of hepatitis C virus (HCV) genotype 3 (GT3) is a medical priority. All-oral treatment of HCV GT3 with daclatasvir (DCV) and sofosbuvir (SOF), with or without ribavirin (RBV), is recommended by several treatment guidelines. The impact of HCV minority populations at amino acid positions in NS5A and NS5B associated with drug resistance on response to DCV+SOF±RBV was assessed in SOF-naive and SOF-experienced HCV patients. METHODS: The presence of baseline NS5A or NS5B polymorphisms was assessed in 227 and 167 HCV-GT3-infected patients, respectively, from four clinical studies of DCV+SOF±RBV...
December 23, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27995270/schnelltest-diagnostik-sexuell-%C3%A3-bertragbarer-infektionen-in-niedrigschwelligen-einrichtungen-gemeinsame-stellungnahme-des-rki-pei-und-der-dstig
#9
Thomas Meyer, Christian G Schüttler, Eberhard Straube, R Stefan Roß, Martin Stürmer, Klaus Jansen, Susanne Buder, Sigrid Nick, Hans-Jochen Hagedorn, Viviane Bremer, Norbert H Brockmeyer
On February 5th, 2016 an expert meeting on rapid diagnostic tests (RDT) for sexually transmitted infections (STI) was held in Berlin at the Robert-Koch-Institute. The aim of the conference was to update a former evaluation of RDTs for diagnosis of HIV, HBV, HCV, T. pallidum, C. trachomatis and N. gonorrhoeae in low-threshold counseling services for STI that had been published after the previous meeting in 2012. According to the strategy to control HIV, hepatitis B and C and other STI, recently adopted by the German Government, there is a lack of test capabilities and a demand for more testing services as well as improved access to testing...
December 19, 2016: Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
https://www.readbyqxmd.com/read/27976461/safety-and-efficacy-of-direct-acting-antivirals-for-the-treatment-of-chronic-hepatitis-c-in-a-real-world-population-aged-65-years-and-older
#10
Fabio Conti, Stefano Brillanti, Federica Buonfiglioli, Ranka Vukotic, Maria Cristina Morelli, Claudine Lalanne, Marco Massari, Francesco Giuseppe Foschi, Veronica Bernabucci, Ilaria Serio, Gian Maria Prati, Elisa Negri, Lorenzo Badia, Paolo Caraceni, Paolo Muratori, Giovanni Vitale, Alberto Porro, Marta Morotti, Giuseppe Mazzella, Pietro Andreone
The availability of direct acting antiviral agents (DAA) regimens has expanded the pool of patients eligible for treatment. However, data on the virological response and tolerability of DAAs in elderly patients are lacking. We evaluated the efficacy and safety of DAAs in patients with advanced fibrosis/cirrhosis in real-life practice with the focus on those aged ≥65 years. Between January and December 2015, all consecutive patients with HCV-related advanced fibrosis/cirrhosis treated with DAA at eleven tertiary referral centers in Emilia Romagna (Italy) were enrolled...
December 15, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27906834/successful-continuation-of-hcv-treatment-following-liver-transplantation
#11
Carlos Fernández Carrillo, Gonzalo Crespo, Juan de la Revilla, Lluís Castells, Maria Buti, José Luis Montero, Emilio Fábrega, Inmaculada Fernández, Cristina Serrano-Millán, Victoria Hernández, José Luis Calleja, María-Carlota Londoño
BACKGROUND: Guidelines recommend that patients with hepatitis C virus (HCV)-related liver disease be treated for HCV before liver transplant (LT) to eliminate the virus prior to surgery. However, the unpredictability of donor organ availability may limit treatment duration. Interruption of HCV treatment with resumption post-LT is one potential solution which has not been investigated widely. METHODS: Patients from 5 clinical centres included in the large, national, noninterventional Hepa-C registry who started treatment with direct-acting antiviral agents (DAAs) while awaiting LT were identified retrospectively and followed up prospectively...
December 1, 2016: Transplantation
https://www.readbyqxmd.com/read/27891360/why-should-viral-markers-be-mandatory-in-ocular-surgeries-a-hospital-based-retrospective-study
#12
Anita Ambastha, Rakhi Kusumesh, Gyan Bhasker
INTRODUCTION: Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus I, II (HIV-I,II) are serious global and public health problem. Knowledge of the seroprevalence would enable early diagnosis, treatment of patients and also help in prevention of horizontal spread of infection by application of universal infection control measures. AIM: To determine the seroprevalence of HBV, HCV and HIV I, II infection in patients undergoing ocular surgery...
October 2016: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/27882839/real-world-drug-costs-of-treating-hepatitis-c-genotypes-1-4-with-direct-acting-antivirals-initiating-treatment-at-fibrosis-0-2-and-3-4
#13
Timothy A Bach, Kathy Zaiken
BACKGROUND: Direct-acting antivirals (DAA) for the treatment of hepatitis C virus (HCV) have drastically improved outcomes but are also very costly. For this reason, priority for treatment is often given to patients with a higher fibrosis score at baseline by payers and providers rather than treating all eligible patients. Simulation studies have suggested that waiting to treat patients until fibrosis 3-4 may be more costly and result in worse outcomes; however, real-world implications are unknown...
December 2016: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/27867437/sero-prevalence-and-correlates-of-hepatitis-b-and-c-co-infection-among-hiv-infected-individuals-in-two-regional-hospitals-in-cameroon
#14
Henry Namme Luma, Servais Albert Fiacre Bagnaka Eloumou, Domin Sone Majunda Ekaney, Fernando Kemta Lekpa, Olivier Donfack-Sontsa, Bertrand Hugo Mbatchou Ngahane, Yacouba Njankouo Mapoure
BACKGROUND: Liver disease related to Hepatitis B (HBV) and C (HCV) infection has become a major cause of morbidity and mortality in HIV/AIDS patients. Data on the prevalence of HBV and HCV in Cameroon remains inconclusive. OBJECTIVE: We aimed to determine the sero-prevalence and correlates of Hepatitis markers in HIV/AIDS patients in two Regional Hospitals. METHODS: A cross-sectional study carried out from December 2014 to March 2015. HIV/AIDS patients aged 21 were included and above, receiving care at HIV treatment centres...
2016: Open AIDS Journal
https://www.readbyqxmd.com/read/27862695/pan-genotypic-treatment-regimens-for-hepatitis-c-virus-advantages-and-disadvantages-in-high-and-low-income-regions
#15
REVIEW
C Hézode
During the last 5 years, the availability of direct-acting antiviral (DAA) agents has revolutionized the treatment of hepatitis C virus (HCV). Compared with interferon/ribavirin-the previous standard of care-DAA combination regimens offer improved sustained virological response (SVR) rates, shorter treatment durations of 8-24 weeks, convenient once-daily single-tablet formulations and more favourable tolerability profiles. HCV treatment is complex, and the choice of therapy must consider a complex range of factors, including baseline viral load, fibrosis stage, the HCV genotype and subgenotype, and the presence of resistance-associated substitutions at baseline...
February 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27810652/alcohol-use-and-hepatitis-c-virus-treatment-outcomes-among-patients-receiving-direct-antiviral-agents
#16
Judith I Tsui, Emily C Williams, Pamela K Green, Kristin Berry, Feng Su, George N Ioannou
BACKGROUND: It is unclear whether alcohol use negatively impacts HCV treatment outcomes in the era of direct antiviral agents (DAAs). We aimed to evaluate the associations between current levels of drinking and treatment response among persons treated for HCV with DAAs in the national Veterans Affairs (VA) healthcare system. METHODS: We identified patients who initiated HCV DAAs over 18 months (1/1/14-6/30/15) and had documented alcohol screening with the Alcohol Use Disorders Identification Test Consumption (AUDIT-C) questionnaire within one year prior to initiating therapy...
December 1, 2016: Drug and Alcohol Dependence
https://www.readbyqxmd.com/read/27806410/to-treat-or-not-to-treat-successful-hepatitis-c-virus-eradication-in-a-patient-with-advanced-hepatocellular-carcinoma-and-complete-response-to-sorafenib
#17
O Waidmann, J Peveling-Oberhag, K Eichler, F Schulze, J Vermehren
Background and aims: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide. Infection with the hepatitis C virus (HCV) is one of the most frequent underlying diseases leading to HCC development. Sorafenib is the standard of care for HCC patients not amenable to local treatment, resection, or liver transplantation. Although overall survival can be increased, objective response rates in patients treated with sorafenib are low. In HCC patients who underwent resection or ablation, HCV eradication with interferon-based regimens reduces the risk of recurrence...
November 2, 2016: Zeitschrift Für Gastroenterologie
https://www.readbyqxmd.com/read/27803742/direct-acting-antivirals-for-the-treatment-of-chronic-hepatitis-c-in-patients-with-chronic-kidney-disease
#18
REVIEW
Anita Kohli, Ali Alshati, Fawaz Georgie, Richard Manch, Robert G Gish
All-oral, direct-acting antivirals (DAAs) have significantly improved the efficacy and safety of chronic hepatitis C (CHC) treatment but their effectiveness and safety among patients with chronic kidney disease (CKD) remains poorly understood. Our aim was to assess the efficacy and safety of DAAs for treatment of CKD patients. The National Library of Medicine through PubMed was searched for studies evaluating the efficacy of DAAs for the treatment of patients with CKD stages 4 or 5, as defined by the Kidney Disease Outcomes Quality Initiative guidelines [i...
November 2016: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/27799966/recommendations-for-the-clinical-management-of-hepatitis-c-in-iran-a-consensus-based-national-guideline
#19
REVIEW
Seyed Moayed Alavian, Behzad Hajarizadeh, Kamran Bagheri Lankarani, Heidar Sharafi, Nasser Ebrahimi Daryani, Shahin Merat, Minoo Mohraz, Masoud Mardani, Mohamad Reza Fattahi, Hossein Poustchi, Mehri Nikbin, Mahmood Nabavi, Peyman Adibi, Masood Ziaee, Bita Behnava, Mohammad Saeid Rezaee-Zavareh, Massimo Colombo, Hatef Massoumi, Abdul Rahman Bizri, Bijan Eghtesad, Majid Amiri, Ali Namvar, Khashayar Hesamizadeh, Reza Malekzadeh
CONTEXT: Hepatitis C virus (HCV) infection is a major public health issue worldwide, including Iran. The new direct-acting antiviral agents (DAAs) with high efficacy have changed the landscape of HCV treatment. This guideline provides updated recommendations for clinical management of HCV infection in Iran. EVIDENCE ACQUISITION: The recommendations of this guideline are based on international and national scientific evidences and consensus-based expert opinion. Scientific evidences were collected through a systematic review of studies that evaluated efficacy and safety of DAA regimens, using PubMed, Scopus and Web of Science...
August 2016: Hepatitis Monthly
https://www.readbyqxmd.com/read/27784957/antiviral-therapy-of-hepatitis-c-as-curative-treatment-of-indolent-b-cell-lymphoma
#20
REVIEW
Michele Merli, Giuseppe Carli, Luca Arcaini, Carlo Visco
The association of hepatitis C virus (HCV) and B-cell non-Hodgkin lymphomas (NHL) has been highlighted by several epidemiological and biological insights; however the most convincing evidence is represented by interventional studies demonstrating the capability of antiviral treatment (AT) with interferon (IFN) with or without ribavirin to induce the regression of indolent lymphomas, especially of marginal-zone origin. In the largest published retrospective study (100 patients) the overall response rate (ORR) after first-line IFN-based AT was 77% (44% complete responses) and responses were sustainable (median duration of response 33 mo)...
October 14, 2016: World Journal of Gastroenterology: WJG
keyword
keyword
64824
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"